AD80, a multikinase inhibitor, as a potential drug candidate for colorectal cancer therapy

•Dysregulation of protein kinases is one of the hallmarks of colorectal cancer.•AD80 is a novel multikinase inhibitor with antineoplastic activity.•Colorectal cancer cells upregulate PI3K/AKT/mTOR and MAPK signaling.•AD80 triggers G2/M arrest, DNA damage, and apoptosis in colorectal cancer cells.•AD80 selectively reduces viability of colorectal cancer cells.